# Rebuilding the health record: medicine's missing feedback loop

> Your health is more than visit notes and lab values. It's the conversations, choices, and data from every part of your life, and the links between them.

- Canonical URL: https://www.meetkin.com/insights/engineering/rebuilding-the-health-record
- Section: [Kin Engineering](https://www.meetkin.com/insights/engineering)
- Written by: Kyle Alwyn and Rahul Devathu
- Published: 2026-11-11
- Published by: Kin Health (https://www.meetkin.com)

Medicine is good at producing information about you and bad at keeping it connected. A symptom gets mentioned in an exam room. A lab value lands in a portal. A prescription goes to a pharmacy. Whether the prescription worked is something you find out at home, weeks later, and usually nobody else ever does.

Each of those pieces is written down somewhere. What almost never gets written down is how they connect: why a drug was started, and what happened after. Without that, your care can't learn from your own experience, and you carry the thread in your head.

The one person who sees all of it is the patient. Health systems change, specialists change, and the people giving advice change. The patient is the only one in every room, and the only one there between the rooms. That makes them the natural quarterback of their own care, but they're playing without any tools or data.

The health graph is our attempt to give them both.

## A record in pieces

Start with how scattered it is. In a year, the median Medicare patient sees seven physicians across four practices.[^pham] Among US adults, 59% have more than one patient portal, and only 7% use an app that brings them together in one place.[^onc]

Moving documents around is the easy part, though. The hard part is that the documents don't say how their contents relate. Take the simplest relationship in medicine: what a drug is for. In a study of 4.4 million outpatient prescriptions, the reason was written on 7.4% of them.[^salazar]

That gap compounds over time. More than one in five US adults aged 40 to 79 takes five or more prescription drugs, and among those 60 and older it's about one in three.[^cdc] When nobody wrote down why each one was started, a medication can outlive its reason, and the list gets hard to safely shorten. In a national survey of VA primary care prescribers, the change they ranked most likely to help them stop medications was requiring every prescription to carry its reason.[^linsky]

This isn't a new problem. In 1968 Lawrence Weed argued in the New England Journal of Medicine that every note, order, and result should be filed under the problem it belongs to.[^weed] His idea won as a format, in the problem list and the SOAP note, and lost as a structure. The links stayed in clinicians' heads.

And that's only what happens inside the system. Health goes home with you. It goes to the dentist, the therapist, the kitchen, and bed. How you slept, what you ate, whether the pain was better on the days you walked: most of what decides how someone actually feels never makes it into a chart.

Meanwhile the person holding it all together is working from memory. A week after a specialist visit, patients recalled about half of what was decided.[^laws] When patients can read their notes, one in five finds a mistake.[^bell]

## What happens after the prescription

Follow one therapy through the system.

It gets prescribed. Somewhere between one in seven and one in four new prescriptions is never filled, and the prescriber often doesn't find out.[^fischer] When the drug is taken, the patient is the one who sees whether it worked, at home and weeks later. If it causes harm, the reporting systems built to catch that miss a median 94% of adverse reactions.[^hazell]

The loop that should run for every patient is simple: prescribe, observe, adjust. In practice it runs on memory, at the next appointment, if there is one. And when someone has a question about how it's going, the answer depends on where they ask. Other patients online reply within hours.[^nobles] A new specialist takes about a month to see.[^amn] Research takes years: trials in leading journals exclude people with common medical conditions 81% of the time,[^vanspall] so the patients hardest to treat are the least studied, and the evidence they do produce takes an average of 15 years to reach half of eligible patients.[^khan] The figure usually quoted is 17 years, an estimate pieced together from earlier studies.[^morris]

**Figure: How long the loop takes, by where you ask**

- Another patient replies: 3 hours. Median time to a first reply, one health community on Reddit.
- A clinician can see you: 31 days. Average wait for a new-patient appointment, six specialties, 15 large US metros.
- Evidence becomes practice: 15 years. Average from landmark study to half of eligible patients, five cancer-control practices.

Logarithmic scale. Three measurements of three different things, set side by side for scale; the article's sources list each one.

## People are desperate for answers

r/ADHD had 600,000 visitors the week we looked.[^adhd] The GLP-1 communities, most of them only a few years old, add up to more than a million and a half memberships.[^glp1] r/Retatrutide drew 138,000 visitors that same week, for a drug that hasn't yet been approved.[^reta]

Spend an hour in any of them and the same post shows up over and over: here's what I have, here's what I was given, here's what happened, has anyone else seen this? Then the replies. I tried that, it took six weeks, the fatigue got worse first, ask about the other dose.

This isn't a fringe habit. 31% of US adults now use social media for health information or advice at least monthly. Asked why, the top answers are learning from people with the same condition (36%) and wanting an answer now (35%). Cost and not having a regular provider come well behind (17%).[^kffsocial] About a third have now asked an AI chatbot the same questions.[^kffai] People are mostly there for two things the system doesn't give them: what happened to people like me, and an answer soon.

A forum can't really give them either. It has no denominators, no way to tell someone like you from someone who isn't, and no memory beyond the thread. A review of 100 studies found online support groups help people socially, with inconclusive effects on physical health.[^mills] And acting on what you read there can hurt: the FDA has reported hospitalizations from people taking five to twenty times the intended dose of compounded semaglutide.[^fda]

The people asking aren't doing anything wrong. The answer they need, what happened to people like them, mostly isn't written down anywhere they can reach.

## What the graph is

Much of what matters about your health doesn't fit in a record: what you value, what worries you, what you're willing to put up with. The graph doesn't try to hold that. It holds the clinical part, as facts and the reasons they connect, so the conversations about everything else have something solid to stand on.

**A fact is a single thing that's true of one person's health.** A symptom, a condition, a medication, a lab result, a vital sign, a procedure, an allergy, a family history, and more. Each one has the same four parts:

- **What:** a concept from a shared medical vocabulary, so "underactive thyroid" in one visit and "hypothyroidism" in another are the same thing.
- **Certainty:** present, possible, or ruled out, with a confidence.
- **When:** when it was true, not when it was recorded.
- **Who:** the clinician, patient, caregiver, or device that said so.

**An edge says why one fact bears on another.** There are five kinds: `evidence_for`, `treats`, `monitors`, `side_effect_of`, and `complication_of`. Together they turn a pile of findings into the reasoning behind someone's care.

**Every fact and edge comes from a source:** a recorded visit, a photographed lab report, a discharge summary. Each source is read once and added as one set of changes. Nothing is edited in place. When a later source corrects an earlier one, the correction is added and the original is marked superseded, so the graph can always say what it believed, when, and on what evidence.

Because the graph is organized around problems rather than visits, it reads as a timeline of one person's health as they lived it. Fatigue that started in January, came up in three visits across two practices, and changed treatment twice is one thread, not three notes in three folders. It's the structure Weed asked for in 1968, with the links finally written down.

The graph belongs to the person, not an institution. That follows from who's constant. A record kept by a health system ends at its walls. A record kept by the patient goes where they go, and can hold what only they saw.

## One person, one path

Here's what that looks like for one fictional person, across five sources over eleven weeks.

**Figure: From a symptom to an outcome, as one path**

1. **A visit: one fact.** She tells her doctor she has been exhausted for two months. The visit is the source; the graph keeps a symptom fact, attributed to the patient, timed to when it began rather than when it was said.
2. **A lab report: a second source.** A photographed lab report arrives a week later. It becomes a lab result fact with a value, a unit, and an interpretation. Nothing links it to the fatigue yet, and the graph does not pretend otherwise.
3. **A diagnosis: the first edges.** At the next visit the clinician names the condition. Two evidence_for edges now say why: the symptom and the lab result both point at it. The reasoning is stored, not just the conclusion.
4. **A therapy.** A medication fact, joined to the condition by a treats edge. From here on the record knows what this drug is for, which is what makes its outcome measurable.
5. **The feedback: an observation.** Eight weeks later a second lab result monitors the condition. The loop has closed once: a therapy went in, a measurement came out, and both sit on the same condition.
6. **And what it cost.** A new symptom, joined to the medication by a side_effect_of edge. Benefit and cost of one therapy for one person are now a path anyone with her permission can walk.

**Six facts, five edges, five sources.** Read it as a path: a symptom and a lab result are evidence for a condition, a medication treats it, a later result monitors it, and a new symptom is that medication's side effect. Step through to watch it accumulate.

Nothing in it is exotic. Every item exists somewhere in a typical patient's paperwork. What's new is the lines, and the lines answer questions a folder of documents can't:

- Why am I taking this? Follow `treats` from the medication.
- What was this diagnosis based on? Follow `evidence_for` back to the facts behind it.
- Is it working? Follow `monitors` to everything measured since.
- What has it cost me? Follow `side_effect_of`.

Those are the questions people bring to a forum at two in the morning. They can be answered from their own record, once the record has a shape.

## From one record to many

A record like that follows one problem over months or years: the condition, what was tried for it, and what happened next, whichever office each piece came from. Medicine almost never has data in that shape. Claims record what was billed. Trials follow selected people for a fixed window, and then stop.

Put many such records side by side, with each person's consent and without their identity, and the question changes. Not "what does the guideline say," but "what happened to people who started this, and to the ones who look like me?"

**Figure: One therapy, a hundred records**

| Of 100 people | Everyone | With a second condition | Treated within 30 days |
| --- | --- | --- | --- |
| Improved, no side effect | 46 | 24 | 63 |
| Improved, with a side effect | 14 | 18 | 13 |
| No measurable change | 26 | 33 | 17 |
| Stopped the therapy | 14 | 25 | 7 |

- Everyone: The average is what a trial reports, and what a guideline is written from.
- With a second condition: The same therapy, a different answer. This group is often too small, or excluded, to show up in a trial.
- Treated within 30 days: Timing is in the graph too: every fact carries when it was true, so how soon is a question you can ask.

Illustrative numbers, not Kin data and not a clinical finding. Each dot stands for one person out of 100 who started the same therapy.

The first view is the one medicine already has: the average effect. The other two are what it mostly lacks, because those people are too few, too complicated, or too far from a research center to end up in a trial. There are plenty of them; their records just aren't connected. Connected, they can answer questions that today have no data behind them: how a treatment went for people with my other conditions, how long a side effect lasted for the people who stayed on it, whether starting sooner made a difference.

Where a field has tracked what happened to every patient, the results are encouraging. Sweden's heart attack registry saw 30-day mortality fall from 15.0% to 8.6% between 1996 and 2007, as evidence-based treatments spread and every hospital could see where it stood.[^jernberg] Cancer patients who reported symptoms between visits, with their care team alerted, lived a median of five months longer.[^basch] Neither result shows that measurement alone was the cause, but both show how much becomes possible once outcomes are visible.

Paying for outcomes depends on the same thing. Contracts that tie a drug's price to whether it works are limited to outcomes that show up in insurance claims, which leaves out most of what patients would call working.[^seeley] You can't pay for outcomes you can't see.

## The missing piece of personalized medicine

Precision medicine is mostly about inputs: sequence the genome, measure more biomarkers, sort people into finer subgroups. Where one feature predicts response, as with many targeted cancer therapies, that has worked remarkably well.

Personalized medicine asks a different question: not which subgroup you're in, but what works for you. People really do respond differently. In a Swedish trial that rotated each participant through four blood pressure drugs, picking each person's best one would have lowered systolic pressure by a further 4.4 mm Hg.[^sundstrom] But it took repeated, blinded exposure of the same person to each drug to show it. An average effect can't tell you who responded;[^senn] only following the same person over time can.

Much of what decides how a treatment goes for someone is also what records leave out: what else they take, how they sleep and eat, when a symptom started, how the bad days compare with the good ones. Those inputs rarely get written down in a form anyone can use, so they never reach precision medicine either. A record that keeps them, tied to the treatment and to what followed, lets care get more specific than a trial average.

So here's our argument, and it's an argument, not a consensus: personalized medicine is a learning problem, and nothing learns without feedback. A system that prescribes and rarely finds out how it went can't get much better at prescribing for you, however much it knows about you going in. And the one person there for every turn of that loop is the patient.

> **What a loop doesn't fix**
>
> Capturing outcomes is necessary, not sufficient. People take a treatment for reasons that also predict how they'll do: observational studies once suggested hormone therapy roughly halved heart disease,[^stampfer] and the randomized trial found harm.[^whi] People blame what they feel on what they take: when patients who'd quit statins over side effects tracked symptoms daily under blinding, 90% of the symptom burden showed up on placebo too.[^wood] People who keep using an app aren't everyone: across eight remote studies, median retention was 5.5 days.[^pratap] And collecting outcomes changes little unless someone acts on them.[^varagunam]
>
> There's also reason for measured optimism. When 32 randomized trials were emulated in insurance claims, the results correlated at 0.82 overall.[^wang] Routine data can answer real questions when it holds the right things and the question is asked carefully. A graph doesn't remove those requirements. It's what makes them possible to meet.

## Where we're starting

We're not there yet, and we have no clinical findings to report. Today the graph does something smaller: it turns a person's visits and documents into one record they own, which they and the people caring for them can read, question, and correct. It gives the one person who's there for all of it something to run their care with. That's worth building on its own.

But the reason to build it as a graph, with facts that carry their time and source and edges that carry their reasons, is everything above. Every prescription is a question, and the patient is the only one who hears the answer. We're building the record that keeps it.

[^pham]: Pham and others, [Care patterns in Medicare and their implications for pay for performance](https://www.nejm.org/doi/full/10.1056/NEJMsa063979), New England Journal of Medicine, 2007.

[^onc]: Office of the National Coordinator for Health IT, [Individuals' access and use of patient portals and smartphone health apps, 2024](https://healthit.gov/data/data-briefs/individuals-access-and-use-patient-portals-and-smartphone-health-apps-2024/), from the 2024 Health Information National Trends Survey.

[^salazar]: Salazar and others, [How often do prescribers include indications in drug orders? Analysis of 4 million outpatient prescriptions](https://pubmed.ncbi.nlm.nih.gov/31361884/), 2019.

[^cdc]: Hales and others, [Prescription drug use among adults aged 40–79 in the United States and Canada](https://www.cdc.gov/nchs/products/databriefs/db347.htm), NCHS Data Brief 347, 2019.

[^linsky]: Linsky and others, [Supporting medication discontinuation: provider preferences for interventions to facilitate deprescribing](https://pmc.ncbi.nlm.nih.gov/articles/PMC5490086/), BMC Health Services Research, 2017.

[^weed]: Weed, [Medical records that guide and teach](https://www.nejm.org/doi/full/10.1056/NEJM196803142781105), New England Journal of Medicine, 1968.

[^laws]: Laws and others, [Factors associated with patient recall of key information in ambulatory specialty care visits](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0191940), PLOS One, 2018.

[^bell]: Bell and others, [Frequency and types of patient-reported errors in electronic health record ambulatory care notes](https://pubmed.ncbi.nlm.nih.gov/32515797/), 2020.

[^fischer]: Fischer and others, [Primary medication non-adherence: analysis of 195,930 electronic prescriptions](https://pmc.ncbi.nlm.nih.gov/articles/PMC2842539/), 2010.

[^hazell]: Hazell and Shakir, [Under-reporting of adverse drug reactions: a systematic review](https://pubmed.ncbi.nlm.nih.gov/16689555/), 2006.

[^nobles]: Nobles and others, [Requests for diagnoses of sexually transmitted diseases on a social media platform](https://jamanetwork.com/journals/jama/fullarticle/2753884), JAMA, 2019. Median time to a first reply in one Reddit health community.

[^amn]: AMN Healthcare, [2025 survey of physician appointment wait times](https://www.amnhealthcare.com/siteassets/amn-insights/physician/ps-2025-physician-appt-wait-times---wp-v6.pdf). Average wait for a new-patient appointment across six specialties in 15 large US metros, from a phone survey of 1,391 offices.

[^vanspall]: Van Spall and others, [Eligibility criteria of randomized controlled trials published in high-impact general medical journals](https://pubmed.ncbi.nlm.nih.gov/17374817/), JAMA, 2007.

[^khan]: Khan, Chambers and Neta, [Revisiting time to translation: implementation of evidence-based practices in cancer control](https://pubmed.ncbi.nlm.nih.gov/33392908/), Cancer Causes & Control, 2021. Five cancer-control practices, with a range of 13 to 21 years.

[^morris]: Morris, Wooding and Grant, [The answer is 17 years, what is the question: understanding time lags in translational research](https://pmc.ncbi.nlm.nih.gov/articles/PMC3241518/), Journal of the Royal Society of Medicine, 2011.

[^adhd]: [r/ADHD](https://www.reddit.com/r/ADHD/), weekly visitors as shown on the community page.

[^glp1]: [GLP-1 Chatter, methods](https://michelnivard.github.io/GLP-1-chatter/methods/).

[^reta]: [r/Retatrutide](https://www.reddit.com/r/Retatrutide/), weekly visitors as shown on the community page.

[^kffsocial]: KFF, [Tracking poll on health information and trust: use of social media and AI for health information and advice](https://www.kff.org/public-opinion/kff-tracking-poll-on-health-information-and-trust-use-of-social-media-and-ai-for-health-information-and-advice/), 2026.

[^kffai]: KFF, [Tracking poll on health information and trust: use of AI for health information and advice](https://www.kff.org/public-opinion/kff-tracking-poll-on-health-information-and-trust-use-of-ai-for-health-information-and-advice/), 2026.

[^mills]: Mills and others, [A mixed studies systematic review on the health and wellbeing effects, and underlying mechanisms, of online support groups for chronic conditions](https://www.nature.com/articles/s44271-025-00217-6), Communications Psychology, 2025.

[^fda]: US Food and Drug Administration, [FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded).

[^jernberg]: Jernberg and others, [Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction](https://doi.org/10.1001/jama.2011.522), JAMA, 2011.

[^basch]: Basch and others, [Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment](https://jamanetwork.com/journals/jama/fullarticle/2630810), JAMA, 2017.

[^seeley]: Seeley and Kesselheim, [Outcomes-based pharmaceutical contracts: an answer to high U.S. drug spending?](https://www.commonwealthfund.org/publications/issue-briefs/2017/sep/outcomes-based-pharmaceutical-contracts-answer-high-us-drug), Commonwealth Fund, 2017.

[^sundstrom]: Sundström and others, [Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial](https://jamanetwork.com/journals/jama/fullarticle/2803518), JAMA, 2023.

[^senn]: Senn, [Statistical pitfalls of personalized medicine](https://www.nature.com/articles/d41586-018-07535-2), Nature, 2018.

[^stampfer]: Stampfer and Colditz, [Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence](https://pubmed.ncbi.nlm.nih.gov/1826173/), 1991.

[^whi]: Writing Group for the Women's Health Initiative Investigators, [Risks and benefits of estrogen plus progestin in healthy postmenopausal women](https://jamanetwork.com/journals/jama/fullarticle/195120), JAMA, 2002.

[^wood]: Wood and others, [N-of-1 trial of a statin, placebo, or no treatment to assess side effects](https://www.nejm.org/doi/full/10.1056/NEJMc2031173), New England Journal of Medicine, 2020.

[^pratap]: Pratap and others, [Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants](https://www.nature.com/articles/s41746-020-0224-8), npj Digital Medicine, 2020.

[^varagunam]: Varagunam and others, [Impact on hospital performance of introducing routine patient reported outcome measures in surgery](https://pubmed.ncbi.nlm.nih.gov/24072815/), Journal of Health Services Research & Policy, 2014.

[^wang]: Wang and others, [Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials](https://jamanetwork.com/journals/jama/fullarticle/2804067), JAMA, 2023.
